<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659958</url>
  </required_header>
  <id_info>
    <org_study_id>E2090-E044-407</org_study_id>
    <nct_id>NCT00659958</nct_id>
  </id_info>
  <brief_title>ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs</brief_title>
  <official_title>Post-authorization, Observational and Prospective Follow up Study to Evaluate Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Farmaceutica, S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to acquire additional information about the appropriate level of
      dosing of Zonisamide when it is prescribed for patients with partial onset epileptic crisis
      who are already being treated with two other antiepileptic drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients from both sexes, 18 to 65 years of age, diagnosed with simple or complex partial
      onset epileptic crisis defined according to the International League Against Epilepsy (ILAE)
      criteria, with a minimum of two seizures within the 4 previous weeks, a stable treatment with
      two antiepileptic drugs for at least 12 weeks, and capable and willing to give their informed
      consent, will be included in the study.

      To these patients, physicians will prescribe zonisamide in the following manner: Titration
      period of 12 weeks, at the end of which all patients must be taking 300 mg. Maintenance doses
      period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose
      from the titration period, lower it to 200 mg, or take it up to 400 mg. Six weeks later
      within this period, a decision will be made to raise the 400 mg doses up to 500 mg if
      considered necessary and tolerable.

      Drugs will be prescribed by the physician and purchased by the patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of seizures.</measure>
    <time_frame>Evaluations will be done at the beginning of the study (enrollment visit) and then one more time when 24 weeks had passed.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life, tolerability.</measure>
    <time_frame>Quality of Life evaluations will be done at the beginning of the study (enrollment visit) and then one more time when 24 weeks have passed. Tolerability will be assessed at the beginning of the study (enrollment visit) and at 12, 18, and 24 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide</intervention_name>
    <description>300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zonegran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients from both sexes, 18 to 65 years of age, diagnosed with simple or complex partial
        onset epileptic seizures defined according to the International League Against Epilepsy
        (ILAE) criteria, with a minimum of two crises within the 4 previous weeks, a stable
        treatment with two antiepileptic drugs for at least 12 weeks and capable and willing to
        give their informed consent, will be included.

        Exclusion Criteria:

        Those who do not fulfill the Inclusion requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesus De Rosendo</last_name>
    <role>Study Chair</role>
    <affiliation>EISAI Farmaceutica S.A. Head of Medical Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario 'Juan Canalejo'</name>
      <address>
        <city>Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. A. Marcide Profesor Novoa Santos</name>
      <address>
        <city>Ferrol</city>
        <state>Galicia</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Sanitario Complexo Hospitalario &quot;XERAL-CALDE&quot;</name>
      <address>
        <city>Lugo</city>
        <state>Galicia</state>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal de Monforte</name>
      <address>
        <city>Lugo</city>
        <state>Galicia</state>
        <zip>27400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Sanitario Hospital Da Costa de Burela</name>
      <address>
        <city>Lugo</city>
        <state>Galicia</state>
        <zip>27880</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <state>Galicia</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <state>Galicia</state>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo (CHUVI), Hospital Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <state>Galicia</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Povisa</name>
      <address>
        <city>Vigo</city>
        <state>Galicia</state>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo (CHUVI), Hospital Xeral-Cies</name>
      <address>
        <city>Vigo</city>
        <state>Galicia</state>
        <zip>63204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>May 9, 2013</last_update_submitted>
  <last_update_submitted_qc>May 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>zonisamide</keyword>
  <keyword>partial onset seizures</keyword>
  <keyword>effectiveness</keyword>
  <keyword>tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

